

STANDARD TREATMENT WORKFLOW (STW)

IMAGE GUIDED MANAGEMENT OF OBSTRUCTIVE JAUNDICE

Sanjiv Sharma¹, Amar Mukund², Pushpinder Singh Khera³, Rengarajan Rajagopal⁴, Pankaj Banode⁵, N Shyam Kumar⁶, Sanjeev Kumar⁷, Manish Shaw⁸, Pradeep Hatimota⁹, Niraj Pandey¹⁰

¹All India Institute of Medical Sciences Delhi; ²Institute of Liver and Biliary Sciences, New Delhi; ³All India Institute of Medical Sciences Jodhpur; ⁴All India Institute of Medical Sciences Jodhpur; ⁵Jawaharlal Nehru Medical College Wardha, Maharashtra; ⁶Christian Medical College Vellore Tamil Nadu; ⁷All India Institute of Medical Sciences Delhi; ⁸NIMS University, Jaipur, Rajasthan; ⁹Apollo Hospital, Guwahati, Assam; ¹⁰All India Institute of Medical Sciences Delhi

CORRESPONDING AUTHOR

Sanjiv Sharma, All India Institute of Medical Sciences Delhi

Email: meetisv@yahoo.com

CITATION

Sharma S, Mukund A, Khera PS, Rajagopal R, Banode P, Kumar NS, Kumar S, Shaw M, Hatimota P, Pandey N. IMAGE GUIDED MANAGEMENT OF OBSTRUCTIVE JAUNDICE . Journal of the Epidemiology Foundation of India. 2024;2(2Suppl):S271-S272.

DOI: <https://doi.org/10.56450/JEFI.2024.v2i2Suppl.009>

This work is licensed under a Creative Commons Attribution 4.0 International License.

©The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.



Standard Treatment Workflow (STW)
IMAGE GUIDED MANAGEMENT OF OBSTRUCTIVE JAUNDICE
ICD-10-K83.1

CLINICAL PRESENTATION

- Jaundice
- Pruritus
- Dark coloured urine & Pale stool

COMMON ETIOLOGIES

- Non obstructive:** Hepatitis related- viral hepatitis (A,B,C,E,NASH), alcohol, auto-immune cirrhosis
- Obstructive:** Mechanical obstruction
- Benign:** stone, sludge, stricture, worm, primary sclerosing cholangitis, bilio-enteric anastomotic stricture (HJ stricture)
- Malignant:** Carcinoma GB, hepatocellular carcinoma, cholangiocarcinoma, hepatic metastasis, pancreatic head carcinoma, extrinsic compression by lymph node/mass, pseudotumor

KEY TO DIAGNOSIS

- In presence of jaundice
- High AST/ALT + relatively normal SAP/GGT suggests hepatitis
- Elevated SAP & GGT + relatively normal AST/ALT suggests obstructive etiology
- USG* abdomen would mostly differentiate between obstructive and non-obstructive causes

Do not suspect obstructive jaundice if:

- AST/ALT elevation > 1000 IU
- ALP/GGT normal/mildly elevated (s/o hepatitis)

If non obstructive jaundice: refer to district hospital/tertiary care to be managed by physician (medicine/gastroenterologist/hepatologist)

RED FLAGS

- Cholangitis
- Pain in right hypochondrium
- Fever
- Chills
- Tachycardia & tachypnoea

Patients should be administered IV fluids & antibiotics- Cefoperazone + Sulbactam in a ratio of 1:1 administered IV 20-40 mg/kg/day in equal doses over duration of 6-12 hrs

INVESTIGATIONS

	ESSENTIAL	DESIRABLE	OPTIONAL
HEMATOLOGICAL	LFT, CBC, PT/INR	KFT, Screen Hepatitis A/E B/C markers	Hepatitis A/E B/C markers
IMAGING	USG Abdomen	MRCP, CECT Abdomen	

PHC

Patient with clinical features and/or red flag signs

CHC/DISTRICT HOSPITAL

- Clinical examination; hematological investigations – LFT, CBC, PT/INR and imaging – USG abdomen
- If cholangitis is suspected – Fluid resuscitation and IV antibiotics and refer to tertiary level care for further management

TERTIARY CARE

- Clinical examination, repeat hematological investigations if > 2 weeks. Imaging – NPTBD to confirm diagnosis & look for level of obstruction, CECT abdomen to decide for definitive vs palliative care
- Suspected cholangitis – Fluid resuscitation & IV antibiotics
- Biliary drainage (PTBD/ERCP) to make patient fit for surgery/palliative care (chemotherapy/radiotherapy)
- PTBD preferred for high CBD/hilar obstruction, ERCP preferred in low CBD obstruction

Once the bilirubin starts reducing, the patient can be taken up for surgery or chemo/radiotherapy or refer back to regional cancer centre

BASIC HEMATOLOGICAL AND USG FINDINGS IN OBSTRUCTIVE JAUNDICE

LFT


- Serum bilirubin – Elevated
- AST/ALT – Normal to elevated
- ALP/GGT – Markedly elevated (ALP>GGT)

CBC

- Hb: Normal to low
- TLC: Normal to elevated
- PT/INR: Normal to elevated

USG ABDOMEN

- Gall bladder stone/mass
- Dilatation of Common bile duct/intrahepatic biliary radicles



Ultrasound image showing causes and findings in obstructive jaundice

COMMON CAUSES OF BILIARY OBSTRUCTION

- GB mass/cholangiocarcinoma causing biliary radicle dilatation (obstruction)
- GB/CBD stone causing biliary dilatation
- Periampullary mass causing biliary dilatation (obstruction)

PERCUTANEOUS TRANSHEPATIC BILIARY DRAINAGE (PTBD)#

INDICATIONS

- Decrease bilirubin to commence appropriate therapy (surgical/palliative)
- Cholangitis (draining infected bile)
- Intense pruritus

DAYS OF HOSPITALISATION

- 1-3 days (non-infected/no cholangitis cases)
- 7-14 days (Cholangitis, can be prolonged in severely septic patients)

CONTRAINDICATIONS

- Deranged coagulation (correct before procedure)
- Emergent cases: infuse fresh frozen plasma (FFP) - 10ml/kg body weight prior to the procedure
- Elective cases: IV vitamin K injection (5-10 mg) - 3 to 5 days
- Ascites (to be drained before therapy)

MANAGEMENT

CLINICAL FEATURES

- LFT: Raised serum bilirubin with/ Markedly raised ALP and/ or GGT
- Normal/ mildly raised AST/ALT
- If signs of cholangitis: Jaundice with fever, rigor, pain

USG

- CBD/IHBR dilatation
- GB stone/Mass

MEDICAL MANAGEMENT FOLLOWED BY

- USG/MRCP
- Lower CBD obstruction: ERCP
- Higher common bile duct/Hilar Obstruction PTBD#

URGENT REFERRAL TO HIGHER CENTRE

MRCP

- Ascertain level and cause of obstruction in the biliary tree
- Lower CBD obstruction: ERCP preferred
- High CBD obstruction: PTBD# preferred

CHOLEDOCHOLITHIASIS/OTHER BENIGN CAUSE NEEDING BILE DRAINAGE

- ERCP
- PTBD# (If ERCP not possible)

BILIARY TRACT MALIGNANCY

CECT ABDOMEN

- Identify the malignancy and extent of disease
- Decide for definitive vs palliative care

DEFINITIVE TREATMENT

- PTBD followed by surgery

PALLIATIVE TREATMENT

- PTBD# followed by Biliary stenting
- Chemotherapy/Radiotherapy

PROCEDURAL DETAILS

- External drainage** for infected cases (aim to establish internal drainage with or without biliary stenting, once the infection is treated. In cases of long-term external drainage – electrolytes should be replaced for ongoing bile salt loss)
- Internal drainage** using internal external drainage catheter for non infected cases else may be considered for primary biliary stenting

EXPECTED OUTCOMES

- Normal bile drainage through the catheter
- Reduction in bilirubin to make patient fit for required therapy

AFTER CARE

- Appropriate antibiotics*: Ofloxacin/Cefixime 200 mg 12 hrly for 3-5 days
- LFT & CBC
- Clinically stable patient with reducing bilirubin can be planned for biliary stenting/ definitive surgery/discharge as per the requirement and suitability

FOLLOW UP

- Follow-up with IR in case of non-reducing or rise in bilirubin/sign of cholangitis/ stent block
- Patients to follow with respective physician (surgeon/medical or radiation oncologist) after successful biliary drainage and normalization of bilirubin

COMPLICATION

- Development of cholangitis post PTBD
- Haemorrhagic output should prompt an immediate evaluation to rule out vascular injury

****Respective contraindications, risks and precautions, pediatric dose of antibiotics to be considered before prescription**

Patients with obstructive jaundice having no/ minimal IHBRD with distended CB may be considered for percutaneous cholecystostomy in emergent situations. Similarly, cholecystostomy may be a bridge to surgery in patients with pycele/mucocele of GB

ABBREVIATIONS

ALP: Alkaline Phosphatase	ERCP: Endoscopic Retrograde Cholangiopancreatography	IR: Interventional Radiology	PT/INR: Prothrombin Time/International Normalized Ratio
ALT: Alanine Aminotransferase	GB: Gall Bladder	KFT: Kidney Function Test	PTBD: Percutaneous Transhepatic Biliary Drainage
AST: Aspartate Aminotransferase	GGT: Gamma Glutamyl Transferase	LFT: Liver Function Test	SAP: Serum Amylase P
CBC: Complete Blood Count (Hemogram)	IHBRD: Intrahepatic Biliary Radicle Dilatation	MRCP: Magnetic Resonance Cholangiopancreatography	USG: Ultrasonography
CBD: Common Bile Duct		NASH: Non Alcoholic Steatohepatitis	
CECT: Contrast Enhanced Computed Tomography			

REFERENCES

- Collier, J.D. and Webster, G. (2010) Liver and Biliary Tract Disease. In: Nickl, R., Brian, R., Stuart, H., et al., Eds., Davidson's Textbook of Medicine, 21st Edition, Churchill Livingstone, New York, 926-933.
- Perez-Johnston R, Delpy AR, Covey AM. Percutaneous Biliary Interventions. Gastroenterol Clin North Am. 2018 Sep;47(3):621-641. doi: 10.1016/j.gtc.2018.04.008. Epub 2018 Jul 7. PMID: 30154414.
- Yadav, Anuksha & Condati, Naveen & Mukund, Amar. (2018). Percutaneous Transhepatic Biliary Interventions. Journal of Clinical Interventional Radiology (JCIR). doi: 10.32743/jc.103556-0338-1642105.
- Funaki B. Percutaneous biliary drainage. Semin Intervent Radiol. 2007 Jun;24(2):268-71. doi: 10.1055/s-2007-980050. PMID: 21326804; PMCID: PMC3036415.
- Madhushan KS, Gamanagatti S, Srivastava DN, Gupta AK. Radiological interventions in malignant biliary obstruction. World J Radiol. 2016 May 28;8(5):518-29. doi: 10.4329/wjr.v8.i5.518. PMID: 27247718; PMCID: PMC4882409.

CHOLANGITIS IN OBSTRUCTIVE JAUNDICE NEEDS AN EARLY BILIARY DRAINAGE

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of ICMR for more information: icmr.gov.in for more information. ©Indian Council of Medical Research, Ministry of Health & Family Welfare, Government of India.